Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Trillium Therapeutics Inc (TRIL) Common Stock NPV

Sell:10.60 CAD Buy:10.84 CAD Change: 0.06 CAD (0.56%)
Market closed |  Prices as at close on 3 July 2020 | Switch to live prices |
Sell:10.60 CAD
Buy:10.84 CAD
Change: 0.06 CAD (0.56%)
Market closed |  Prices as at close on 3 July 2020 | Switch to live prices |
Sell:10.60 CAD
Buy:10.84 CAD
Change: 0.06 CAD (0.56%)
Market closed |  Prices as at close on 3 July 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (''do not eat'') signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (''eat'') signals. A Phase one clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with cancer is ongoing, and a second Phase one trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17.

Contact details

Address:
2488 Dunwin Dr
MISSISSAUGA
L5L 1J9
Canada
Telephone:
+1 (416) 5950627
Website:
www.trilliumtherapeutics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
TRIL
ISIN:
CA89620X5064
Market cap:
909.64 million CAD
Shares in issue:
83.44 million
Sector:
Biotechnology
Exchange:
Toronto Stock Exchange
Country:
Canada
Currency:
Canadian dollars
Indices:
n/a

Key personnel

  • Robert Kirkman
    Executive Chairman of the Board
  • Calvin Stiller
    Independent Chairman of the Board
  • Jan Skvarka
    President, Chief Executive Officer, Director
  • James Parsons
    Chief Financial Officer
  • Malik Slassi
    Senior Vice President - Discovery Research
  • Scott Duncan
    Director of Intellectual Property
  • Penka Petrova
    Chief Development Officer
  • Yaping Shou
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.